Repligen Co. (NASDAQ:RGEN) to Post Q3 2024 Earnings of $0.42 Per Share, William Blair Forecasts

Repligen Co. (NASDAQ:RGEN) – Stock analysts at William Blair raised their Q3 2024 earnings per share (EPS) estimates for Repligen in a research report issued to clients and investors on Thursday, May 2nd. William Blair analyst M. Larew now expects that the biotechnology company will post earnings per share of $0.42 for the quarter, up from their previous forecast of $0.38. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. William Blair also issued estimates for Repligen’s Q4 2024 earnings at $0.47 EPS, FY2024 earnings at $1.46 EPS and FY2025 earnings at $2.24 EPS.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm’s revenue was down 17.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.64 earnings per share.

Several other brokerages also recently weighed in on RGEN. JPMorgan Chase & Co. reduced their target price on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Finally, Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $197.75.

Repligen Stock Down 0.2 %

Shares of RGEN stock opened at $167.72 on Monday. The stock has a 50 day moving average of $179.84 and a 200 day moving average of $174.62. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.37 billion, a P/E ratio of 670.91, a P/E/G ratio of 5.58 and a beta of 1.03. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13.

Insider Transactions at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO James Bylund sold 4,373 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 in the last quarter. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. YHB Investment Advisors Inc. acquired a new stake in Repligen in the 1st quarter valued at approximately $26,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 146 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares during the period. Principal Securities Inc. acquired a new position in Repligen during the 4th quarter worth about $48,000. Finally, Milestone Investment Advisors LLC purchased a new position in Repligen during the 3rd quarter valued at about $61,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.